{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T20:41:54Z","timestamp":1779396114869,"version":"3.53.1"},"reference-count":28,"publisher":"Baishideng Publishing Group Inc.","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Clin Oncol"],"abstract":"<jats:p>BACKGROUND<\/jats:p>\n          <jats:p>Chemotherapy combined with anti-angiogenic therapy has become an important strategy for the treatment of advanced gastric cancer (AGC); however, the regimen needs optimization.<\/jats:p>\n          <jats:p>AIM<\/jats:p>\n          <jats:p>To evaluate the efficacy of albumin-bound paclitaxel (nab-ptx) combined with the small molecule vascular endothelial growth factor inhibitor anlotinib in second-line and beyond treatment of AGC.<\/jats:p>\n          <jats:p>METHODS<\/jats:p>\n          <jats:p>We collected data from AGC patients at our hospital who experienced disease progression after first-line chemotherapy and received anlotinib combined with nab-ptx. The primary endpoints included overall survival (OS) and progression-free survival (PFS), while the secondary endpoints were objective response rate (ORR), disease control rate (DCR), and adverse events (AEs).<\/jats:p>\n          <jats:p>RESULTS<\/jats:p>\n          <jats:p>Preliminary results indicated that anlotinib combined with nab-ptx can provide significant efficacy in second-line or above treatment for AGC (median PFS = 6.0 months, median OS = 12.0 months), with an ORR of 42% and a DCR of 78%. Further analysis revealed that patients who experienced hypertension, proteinuria, and hand-foot syndrome during treatment had better efficacy compared to those who did not experience these AEs. Mechanistic studies suggest that this regimen likely exerts synergistic anti-tumor effects by activating the immune response through the reduction of regulatory T-cell proportions. Common adverse reactions included bone marrow suppression, peripheral neuropathy, hypertension, proteinuria, and hand-foot syndrome, which were manageable and resolved with appropriate interventions, indicating the promising application of this regimen in second-line or above treatment for AGC.<\/jats:p>\n          <jats:p>CONCLUSION<\/jats:p>\n          <jats:p>The combination of anlotinib and nab-ptx shows promising efficacy with fewer toxicities in AGC treatment. The regimen holds promise as a second-line treatment of AGC; however, its specific clinical value requires further research.<\/jats:p>","DOI":"10.5306\/wjco.v16.i4.102199","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T01:01:31Z","timestamp":1742950891000},"source":"Crossref","is-referenced-by-count":1,"title":["Combination of anlotinib and albumin-bound paclitaxel in 2<sup>nd<\/sup> line and above treatment of advanced gastric cancer: A retrospective study"],"prefix":"10.5306","volume":"16","author":[{"given":"Wen-Ming","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Rui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Bing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103841"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v29.i16.2452"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.004"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2020.11685"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2241"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2022_211012N1441"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.41711"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-03887-2"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2217\/nnm-2022-0300"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S472196"},{"key":"B11","unstructured":"Ismail U, Killeen RB.   Taxane Toxicity. 2023 Mar 12. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S426898"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-022-02114-y"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.885350"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac136"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01857-6"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112635"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2174\/1389201021666200623132803"},{"key":"B19","unstructured":"Gu W, Yang J, Wang Y, Xu J, Wang X, Du F, Hu X, Guo H, Song C, Tao R, Zhang X. Comprehensive identification of FGFR1-4 alterations in 5 557 Chinese patients with solid tumors by next-generation sequencing. Am J Cancer Res 2021; 3893-3906"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2021.102076"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2021.12.005"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-22-499"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2022.895982"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.05.013"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-24-497"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-021-02224-x"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-034685"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-22-279"}],"container-title":["World Journal of Clinical Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/2218-4333\/full\/v16\/i4\/102199.htm","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.wjgnet.com\/2218-4333\/full\/v16\/i4\/102199.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T01:01:55Z","timestamp":1742950915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/2218-4333\/full\/v16\/i4\/102199.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":28,"journal-issue":{"issue":"4"},"alternative-id":["102199"],"URL":"https:\/\/doi.org\/10.5306\/wjco.v16.i4.102199","relation":{},"ISSN":["2218-4333"],"issn-type":[{"value":"2218-4333","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,24]]}}}